4-7-10-13-16-19-docosahexaenoic-acid-dopamine-conjugate and Neoplasms

GPR55 is a GPCR of the non-CB1/CB2 cannabinoid receptor family, which is activated by lysophosphatidylinositol (LPI) and stimulates the proliferation of cancer cells. Anandamide, a bioactive lipid endocannabinoid, acts as a biased agonist of GPR55 and induces cancer cell death, but is unstable and psychoactive. We hypothesized that other endocannabinoids and structurally similar compounds, which are more hydrolytically stable, could also induce cancer cell death via GPR55 activation. We chemically synthesized and tested a set of fatty acid amides and esters for cell death induction via GPR55 activation. The most active compounds appeared to be

Topics: Animals; Antineoplastic Agents; Apoptosis; Cannabinoid Receptor Agonists; Cell Line, Tumor; Dopamine; Enzyme Activators; Fatty Acids; Humans; Molecular Docking Simulation; Neoplasms; Nitric Oxide Synthase Type I; PC12 Cells; Rats; Receptors, Cannabinoid